Thursday 16 October, 2025
Introduction: Hepatic impairment may be associated with a reduced rate of drug metabolism. In particular, it has been demonstrated that…
Read moreAbstracts
PBPK modeling based clinical dose adaptation in liver cirrhosis patients for seven CYP and UGT enzyme substrates
Thursday 16 October, 2025
Introduction: In patients with impaired liver function, understanding the pharmacokinetics (PK) is crucial for effective and safe medication management. Liver…
Read morePopulation Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients
Thursday 16 October, 2025
Objectives: Introduction: Methicillin-resistant staphylococcus aureus (MRSA) infections are one of the leading causes of pulmonary exacerbations (PEx) in persons with…
Read moreA physiologically-based pharmacokinetic model for prediction of cannabidiol pediatric dose
Thursday 16 October, 2025
Objectives: To develop a PBPK model for CBD to predict age-dependent pediatric dosage regimens by modifying a previously PBPK model…
Read moreDevelopment of a physiologically-based pharmacokinetic model to understand and predict the disposition of gallium-68 radiolabeled-dendrimers in vivo
Thursday 16 October, 2025
Introduction/Objectives: In the past twenty years, numerous diverse nanoparticles (NPs) have been designed in order to improve the pharmacokinetic (PK) profile…
Read morePopulation pharmacokinetics of belantamab mafodotin in relapsed or refractory multiple myeloma patients with severe renal impairment
Thursday 16 October, 2025
Objectives: Belantamab mafodotin is an antibody-drug conjugate (ADC) consisting of an afucosylated humanized anti-B‐cell maturation antigen (BCMA) monoclonal antibody (mAb)…
Read morePredicting individual disease progression including parameter uncertainty in rare neurodegenerative diseases: the example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS)
Thursday 16 October, 2025
Objectives: Genetic cerebellar ataxias are ultra-rare progressive neurological diseases (RNDs) affecting the cerebellum, often with multisystemic damage to other neurological…
Read moreEvaluation of treatment effects in genetic ataxias using SARA score modelling: comparison of multiple trial designs by a large trial simulation framework
Thursday 16 October, 2025
Objectives: Genetic cerebellar ataxias are progressive rare neurological diseases affecting the cerebellum, often with multi-systemic damage to other neurological systems,…
Read moremlcov: New Machine Learning Based R package for Covariate Selection
Thursday 16 October, 2025
Introduction In the last few years, several alternatives have been proposed to address the weaknesses of the most widely used…
Read moreEvaluation of the Boruta Machine Learning Algorithm for Covariate Selection
Thursday 16 October, 2025
Introduction Stepwise covariate modeling methodology (SCM) [1] is one of the most used approaches in covariate selection. Despite its use,…
Read more